Results
Seventy-four patients were randomized to ILIT with three doses of 0.1 ml
of birch- and 5-grass pollen allergen extracts, or either and placebo at
monthly intervals. One patient withdrew consent after the first
injections and one was lost to follow-up after two injections.
Seventy-two patients received all injections (Fig. 1). One patient was
lost to follow-up two years after treatment; RQLQ and RTSS had been
halved and the patient had not required or used anti-allergic
medication. Another patient was lost to follow-up three years after ILIT
and two years after treatment showed no improvement in RTSS, MS or RQLQ.
Hence, 70 patients remained for analyses three years after treatment.